NCT05522192 - Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 21, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

May 31, 2026

Conditions

Relapsed or Refractory Acute Myeloid Leukemia

Interventions

DRUG

Mitoxantrone liposome

Phase I: 24mg/m2, 30 mg/m2, 36mg/m2, IV, d1; Phase II: RP2D.

DRUG

Venetoclax

Phase I/II: 100mg po d1，200mg po d2，400mg po d3-28.

Trial Locations (1)

RECRUITING

First Affiliated Hospital of Jinan University, Guangzhou